Berenberg Bank analyst Sam England maintained a Buy rating on Qiagen (QGEN – Research Report) today and set a price target of €54.20. The company’s shares opened today at $44.72.
According to TipRanks, England is ranked #7108 out of 8594 analysts.
In addition to Berenberg Bank, Qiagen also received a Buy from Morgan Stanley’s Aisyah Noor in a report issued on January 8. However, on January 9, Kepler Capital maintained a Hold rating on Qiagen (NYSE: QGEN).
See the top stocks recommended by analysts >>
The company has a one-year high of $50.82 and a one-year low of $34.74. Currently, Qiagen has an average volume of 1.35M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Qiagen (QGEN) Company Description:
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN:
- Qiagen rumor highlighted in Betaville blog
- QIAGEN N.V. to release results for Q4 2023 and hold webcast
- Qiagen receives FDA clearance for NeuMoDx CT/NG Assay 2.0
- QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
- Qiagen announces plans to return approximately $300M to shareholders
